FY2027-H1First statedAnnual report
「Japan's regenerative medicine industry has established systems to bring outstanding regenerative medicine products into practical use quickly. These include the conditional and time-limited approval system introduced under the revised PMD Act enacted in 2014, and the Pioneer Drug Designation System, legislated in 2019, which provides priority support such as shorter approval review periods and advance consultations with the authorities. Against this backdrop, multiple iPS cell-based products received conditional and time-limited approval in March 2026, further demonstrating concrete progress toward social implementation.」
The Company describes the industry environment in which multiple iPS cell-based products received conditional and time-limited approval in March 2026, indicating concrete progress toward the social implementation of regenerative medicine.